News
- LFB marks a return to a trend of profitable growth in 2012 - 04/23/2013
- Shin Poong and LFB Signed a Strategic Alliance Agreement - 03/27/2013
- Thallion and LFB terminate Shigamabs collaboration - 02/21/2013
- Shin Poong and LFB Agree on Joint Venture Term Sheet for the Manufacturing of Biotech Medicinal Products - 01/09/2013
- GTC Biotherapeutics, Inc., an LFB Group Company, Announces Name Change to rEVO Biologics and Renewed Commitment to Evolving Recombinant Medicine - 01/04/2013
- Internal moves in LFB Group - 12/19/2012
- C4C Consortium: 5 medicinal products under development for France’s cell therapy industrialisation sector - 10/31/2012
- LFB finalist of the 12th International Prix Galien - 10/09/2012
- The LFB Jacques Oudin Prize 2012: two winners in clinical and basic immunology - 10/04/2012
- Opening of the WFH Congress in Paris on July 8th, LFB group Platinum Sponsor - 07/10/2012
- Christian BECHON appointed Chairman and Chief Executive Officer of LFB for a second mandate - 03/19/2012
- TG Therapeutics Completes Licensing Agreement With LFB BIOTECHNOLOGIES for the Development of Ublituximab - 03/01/2012
- Cell therapies: LFB is investing in a major cell therapy drug production project as part of an agreement with two biotechnology companies and seven public hospitals - 03/01/2012
- Thallion and LFB compete patient enrollment of Phase II Shigatec trial - 01/09/2012
- LFB Announces U.S. Patent on Monoclonal Antibodies with Enhanced Activity - 07/08/2011
- The Prix Galien was awarded to LFB in the "Medicine for the Treatment of Rare Diseases" category - 05/25/2011
- Thallion announces first patient enrolled in high dose cohort of phase II Shigatec trial - 05/30/2011
- GTC BIOTHERAPEUTICS Inc., a LFB group company, granted protection until 2027 on broad transgenic protein production patent - 05/19/2011
- THALLION AND LFB INITIATE PHASE II SHIGATEC TRIAL - 11/29/2010
- LFB's recombinant anti-CD20 monoclonal antibody is granted orphan drug status in the USA for Chronic Lymphocytic Leukemia - 08/06/2010
- LFB Launches Process to buy out Austrian Plasma Collection Group to support its International Activity - 06/22/2010
- Sanofi-aventis and LFB industrial cooperation project in bio-production in France comes to fruition - 04/22/2010
- THALLION Pharmaceuticals and LFB BIOTECHNOLOGIES sign definitive agreement to develop and commercialize treatment for E.Coli infection - 02/16/2010
- FDA grants Orphan Drug Designation to LFB’s « Complement Factor H » - 02/09/2010
- Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments - 02/02/2010
- LFB’s recombinant anti-CD20 monoclonal antibody is granted orphan drug status in Europe for Chronic Lymphocytic Leukemia - 11/25/2009
- Sanofi-aventis and LFB announce an industrial cooperation project for bioproduction in France - 10/28/2009
- MAbgène expands its GMP facilities to produce phase III clinical and commercial batches of biomolecules - 10/14/2009
- GTC Biotherapeutics announces changes in board - 10/01/2009
- Hopes for prophylaxis and therapy for Chikungunya - 09/28/2009
- "Le Rire Médecin" in Brazil with LFB's support - 08/25/2009
- Francis Mer Joins the Board of Directors of LFB S.A. - 07/29/2009
- GTC Biotherapeutics enters agreements with LFB for funding of $12.3 million with an option for LFB to fund an additional $6.4 million - 06/18/2009
- Recall of medicinal product batches following a case of the classic form of Creutzfeldt-Jakob Disease (sporadic CJD) in a French blood donor - 06/12/2009
- A resounding “Thank you for the gift of life!” to French blood donors from the patients of the IRIS association supported by LFB - 06/11/2009
- Securization of Plasma-Derived Medicinal Products - 02/19/2009
- Therapure Biopharma Inc. and LFB Biotechnologies announce a development services contract for a new therapeutic protein - 02/18/2009
- First in man injections of LFB's first two therapeutic monoclonal antibodies - 02/10/2009